Nkarta, Inc. Operating Cash Flow
Nkarta, Inc. (NKTX) reported Operating Cash Flow of -$52.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Nkarta, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$24.22M.
- Nkarta, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$28.20M.
- Nkarta, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$21.65M.
- Nkarta, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$18.69M.
- Nkarta, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$88.70M.
- Nkarta, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$99.70M.
- Nkarta, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$86.16M.
- Nkarta, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$57.00M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$24.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$52.42M 10-Q · filed 2026-08-10 | -$74.07M derived: sum of 3 quarters · filed 2026-08-10 | -$92.76M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$28.20M 10-Q · filed 2026-05-12 | -$49.85M derived: sum of 2 quarters · filed 2026-05-12 | -$68.53M derived: sum of 3 quarters · filed 2026-05-12 | -$87.29M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | -$21.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$40.33M derived: sum of 2 quarters · filed 2026-03-25 | -$59.09M derived: sum of 3 quarters · filed 2026-08-10 | -$88.70M 10-K · filed 2026-03-25 | |
| 2025-09-30 | -$18.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$37.44M derived: sum of 2 quarters · filed 2026-08-10 | -$67.05M 10-Q · filed 2025-11-10 | -$91.80M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$18.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$48.37M 10-Q · filed 2026-08-10 | -$73.12M derived: sum of 3 quarters · filed 2026-08-10 | -$97.66M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | -$29.61M 10-Q · filed 2026-05-12 | -$54.36M derived: sum of 2 quarters · filed 2026-05-12 | -$78.91M derived: sum of 3 quarters · filed 2026-05-12 | -$100.80M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$24.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$49.30M derived: sum of 2 quarters · filed 2026-03-25 | -$71.19M derived: sum of 3 quarters · filed 2026-03-25 | -$99.70M 10-K · filed 2026-03-25 | |
| 2024-09-30 | -$24.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$46.44M derived: sum of 2 quarters · filed 2025-11-10 | -$74.94M 10-Q · filed 2025-11-10 | -$98.30M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$21.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$50.40M 10-Q · filed 2025-08-12 | -$73.75M derived: sum of 3 quarters · filed 2025-08-12 | -$94.03M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$28.51M 10-Q · filed 2025-05-14 | -$51.86M derived: sum of 2 quarters · filed 2025-05-14 | -$72.14M derived: sum of 3 quarters · filed 2025-05-14 | -$93.91M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$23.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$43.63M derived: sum of 2 quarters · filed 2025-03-26 | -$65.40M derived: sum of 3 quarters · filed 2025-03-26 | -$86.16M 10-K · filed 2025-03-26 | |
| 2023-09-30 | -$20.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$42.05M derived: sum of 2 quarters · filed 2024-11-07 | -$62.81M 10-Q · filed 2024-11-07 | -$70.14M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$21.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$42.53M 10-Q · filed 2024-08-13 | -$49.86M derived: sum of 3 quarters · filed 2024-08-13 | -$64.66M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$20.76M 10-Q · filed 2024-05-09 | -$28.09M derived: sum of 2 quarters · filed 2024-05-09 | -$42.89M derived: sum of 3 quarters · filed 2024-05-09 | -$59.50M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$22.13M derived: sum of 2 quarters · filed 2024-03-21 | -$38.74M derived: sum of 3 quarters · filed 2024-03-21 | -$57.00M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$14.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$31.41M derived: sum of 2 quarters · filed 2023-11-09 | -$49.67M 10-Q · filed 2023-11-09 | -$67.24M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$16.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$34.87M 10-Q · filed 2023-08-10 | -$52.44M derived: sum of 3 quarters · filed 2023-08-10 | -$70.70M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$18.26M 10-Q · filed 2023-05-11 | -$35.83M derived: sum of 2 quarters · filed 2023-05-11 | -$54.09M derived: sum of 3 quarters · filed 2023-05-11 | -$71.54M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$17.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$35.83M derived: sum of 2 quarters · filed 2023-03-16 | -$53.28M derived: sum of 3 quarters · filed 2023-03-16 | -$67.93M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$18.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$35.71M derived: sum of 2 quarters · filed 2022-11-09 | -$50.35M 10-Q · filed 2022-11-09 | -$63.21M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | -$17.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$32.10M 10-Q · filed 2022-08-11 | -$44.95M derived: sum of 3 quarters · filed 2022-08-11 | -$57.08M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$14.65M 10-Q · filed 2022-05-12 | -$27.50M derived: sum of 2 quarters · filed 2022-05-12 | -$39.63M derived: sum of 3 quarters · filed 2022-05-12 | -$49.87M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$12.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$24.98M derived: sum of 2 quarters · filed 2022-03-17 | -$35.22M derived: sum of 3 quarters · filed 2022-03-17 | -$43.51M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$12.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$22.36M derived: sum of 2 quarters · filed 2021-11-10 | -$30.65M 10-Q · filed 2021-11-10 | -$37.29M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$10.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$18.53M 10-Q · filed 2021-08-12 | -$18.53M 10-Q · filed 2020-08-20 | -$25.16M derived: sum of 3 quarters · filed 2021-08-12 | -$29.81M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$8.29M 10-Q · filed 2021-05-13 | -$14.92M derived: sum of 2 quarters · filed 2021-05-13 | -$19.57M derived: sum of 3 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$11.28M derived: sum of 2 quarters · filed 2021-03-25 | -$18.37M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$4.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$11.73M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$7.08M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |